在代谢功能障碍相关的乳脂肝炎中使用西马格卢:叙述性综述
George S Zacharia1,2, Sudharsan R Gongati1, Aayush Kharel1
1Internal Medicine, BronxCare Health System, New York City, USA.
Cureus
|December 1, 2025
概括
作为一种类似葡萄糖类-1 (GLP-1) 受体激动剂的塞马格卢提德,有效治疗2型糖尿病和与代谢功能障碍相关的脂肪肝炎 (MASH). 它提供超出血糖控制的好处,包括减肥和改善肝纤维化.
科学领域:
- 内分泌学和肝病学 在内分泌学和肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖类-1 (GLP-1) 是一种对葡萄糖平衡至关重要的内激素.
- GLP-1受体激动剂 (例如,赛马格卢提德) 已被开发用于治疗应用.
- 塞马格卢提德提供独特的口服可用性和广泛的临床疗效.
研究的目的:
- 审查塞马格卢提德的多方面的治疗应用.
- 突出塞马格卢提德在2型糖尿病 (T2DM) 和代谢功能障碍相关的脂肪肝炎 (MASH) 的疗效.
- 讨论塞马格卢提德在肝脏疾病中的安全性和临床意义.
主要方法:
- 临床研究和治疗指南的文献综述.
- 对塞马格卢提德的药理作用和临床试验数据的分析.
- 评估安全考虑和批准的指示.
主要成果:
- 在T2DM中,塞马格卢提德显示出显著的血糖控制,体重减轻和心血管风险降低.
- 在MASH患者中,塞马格卢提德治疗导致脂肪肝炎的消失和肝纤维化改善.
- 塞马格卢提德已被批准用于治疗中度至晚期纤维化非脊髓炎性MASH.
结论:
- 塞马格卢提德是T2DM和MASH的有价值的治疗剂.
- 它在改善肝脏参数方面的有效性使其成为MASH的关键治疗方法.
- 塞马格卢提德扩大了肝脏病学家管理常见肝脏疾病的治疗选择.
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Chronic Pancreatitis II: Collaborative Care
291
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
291
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
Chronic Pancreatitis I: Introduction
648
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
648
Acute Pancreatitis II: Clinical Manifestations and Management
705
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
705
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161


